BioSpace News Archive

PureTech Health plc noted today that its Founded Entity, Vedanta Biosciences today announced that it has raised $106.5 million to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activities.

Vedanta Biosciences today announced that it has raised $106.5 million to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activities.

Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the first quarter ended March 31, 2023, and updated full-year guidance.

Agios Pharmaceuticals, Inc. today announced that the company is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2024, at 9 a.m. ET.

Achilles Therapeutics plc today announced that United States (US) patent 11,634,773 has been granted.

Invivyd, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for VYD222, a monoclonal antibody (mAb) candidate.

Reviva Pharmaceuticals Holdings, Inc. today announced it will host a KOL webinar on brilaroxazine (RP5063), a serotonin-dopamine modulator in late-stage development for schizophrenia, on May 2 nd at 11:00am ET.

Bend Health, Inc. (“Bend”), a national provider of pediatric mental health care services for children and families, today announced results of a new study showing that collaborative, digital mental health interventions improved symptoms in children and teens with attention-deficit/hyperactivity disorder (ADHD).

Alkermes plc (Nasdaq: ALKS) today announced that on April 19, 2023 it received a second interim award (the “Second Interim Award”) from the arbitral tribunal (the “Tribunal”) in its arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V.

DecisionDx ® -Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients.